

# EVIDENCE FOR THE INVOLVEMENT OF PPARs IN THE PHOTOPROTECTIVE ACTIVITY OF BIO201 (NORBIXIN) ON RETINAL PIGMENT EPITHELIUM.


Fontaine V.<sup>1</sup>, Monteiro E.<sup>1</sup>, Fournie M.<sup>1</sup>, On S.<sup>2</sup>, Serova M.<sup>2</sup>, Dilda P.<sup>2</sup> and Lafont R.<sup>2</sup>

 <sup>1</sup> Sorbonne Universités, UPMC Univ. Paris 06, INSERM, CNRS, Institut de la Vision, 17 Rue Moreau, 75012 Paris, France
<sup>2</sup> Biophytis, Université Pierre et Marie Curie, 4 place Jussieu, 75005 Paris, France

Financial disclosure: Financial support came from Biophytis.

# INTRODUCTION


According to Herzlich (PPAR Res. 2008 Article ID 389507), PPARs play a key role in the protection of RPE cells against Age-Related Macular Degeneration



PPARs comprise three subtypes that can accommodate various types of ligands. The aim of the present work was to investigate the respective roles of PPAR $\alpha$ , PPAR $\beta/\delta$  and PPAR $\gamma$  in response to BIO201 (norbixin) on the protection against the deleterious effects of A2E.

A2E sensitizes RPE cells to blue light damage and reduces PPAR $\alpha$  protein levels. Both effects are blunted by BIO201, a preparation of the diapocarotenoid norbixin developed by Biophytis<sup>1</sup>.

No significant effect is observed on other PPARs levels.




NBX: norbixin 20 μM A2E: 30 μM

The effect on PPAR $\alpha$  is post-translational and is also observed with inverted protocols (where treatment with A2E precedes that with norbixin)

<sup>1</sup>(Fontaine et al., PLoS ONE 2016, DOI:10.1371/journal.pone.0167793).

## BIO201 (norbixin) activates hPPAR $\alpha$ and even more efficiently hPPAR $\beta/\delta$



Such experiments do not tell us whether these effects are direct or indirect

**DIRECT BINDING TESTS** (competition with radioactive ligands): BIO201 (norbixin) binds to PPAR $\alpha$  with a K<sub>i</sub> of 16.5 µM, and to PPAR $\gamma$  with a K<sub>i</sub> of 1.15 µM

**FRET ACTIVITY TESTS** (induction of PPAR coactivator or corepressor recruitment):

BIO201 (norbixin) shows no agonist effect on any of the three PPARs, but has an antagonist effect on PPAR $\beta/\delta$  (K<sub>a</sub> *ca*. 3.2 µM)

# CompoundEffectPPARα agonistSulindac does not protect RPE cells and does not maintain<br/>PPARα levelsPPARα antagonistMK886 protects RPE cells and maintains PPARα levelsPPARβ/δ agonistGW0742 protects RPE cells and maintains PPARα levelsPPARβ/δ antagonistGSK3787 reduces protection by norbixinPPARγ agonistTroglitazone protects RPE cells and maintains PPARα levelsPPARγ antagonistTo070907 reduces protection by norbixin and troglitazone

## Effect of various pharmacological agents

**APOPTOSIS**: BIO201 (norbixin) cytoprotective activity correlates with a significant reduction of both ROS levels (p<0.01) and apoptosis induction upon treatment with antimycin A.

# CONCLUSIONS

• These experiments have revealed the difficulty of interpreting experimental data, arising from the limited specificity of current PPAR agonists and antagonists, a potential source of multiple cross-reactions (e.g. troglitazone).

• There is some discrepancy between activation studies and binding experiments, which suggests that PPAR activation is mostly indirect.

• A2E induces PPAR $\alpha$  degradation, and all the tested compounds showing a protection of RPE cells against blue light damage in the presence of A2E are able to sustain PPAR $\alpha$ levels. Thus the presence of PPAR $\alpha$  appears required for photoprotection.

• Agonists of PPAR $\gamma$  and PPAR $\beta/\delta$  protect RPE cells, whereas their antagonists reduce the protective effect of BIO201 (norbixin). Thus, both PPARs seem involved in BIO201 action.

• Additional strategies (siRNA, shRNA, ...) are under way in order to relieve remaining ambiguities and assess definitively the role of the three PPARs in BIO201 (norbixin) protective action.

• **Norbixin** is the active principle of **BIO201**, a 97% pure 9'-cis isomer prepared from the seeds of *Bixa orellana*. BIO201 has been formulated for improving its stability and *per os* bioavailability as **Macuneos**. Biophytis will start a phase 1 clinical trial in 2017 with Macuneos as an oral treatment for dry AMD.

<u>Contacts</u>: valerie.fontaine@inserm.fr – pierre.dilda@biophytis.com